Cargando…
Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet
BACKGROUND AND OBJECTIVE: Venetoclax is an approved BCL-2 inhibitor, currently under evaluation in different hematological malignancies in adult and pediatric populations. Venetoclax is available as 10, 50, and 100 mg tablets. To provide an alternative to patients who find taking the commonly prescr...
Autores principales: | Badawi, Mohamed, Chen, Xin, Marroum, Patrick, Suleiman, Ahmed A., Mensing, Sven, Koenigsdorfer, Anette, Schiele, Julia Teresa, Palenski, Tammy, Samineni, Divya, Hoffman, David, Menon, Rajeev, Salem, Ahmed Hamed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338003/ https://www.ncbi.nlm.nih.gov/pubmed/35829925 http://dx.doi.org/10.1007/s40261-022-01172-4 |
Ejemplares similares
-
Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients
por: Badawi, Mohamed, et al.
Publicado: (2023) -
Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019) -
Safety evaluation of the interchangeable use of robenacoxib (Onsior™) tablets and solution for injection in dogs
por: Toutain, Céline E., et al.
Publicado: (2017) -
Relative bioavailability of ertugliflozin tablets containing the amorphous form versus tablets containing the cocrystal form
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2022) -
Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis
por: Dave, Nimita, et al.
Publicado: (2019)